Published in
Taylor and Francis Group, Leukemia & Lymphoma, 8(61), p. 1850-1859, 2020
DOI: 10.1080/10428194.2020.1747066
Links
Tools
Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
Journal article published in 2020 by
Katja Weisel,
Meletios Dimopoulos 
,
Philippe Moreau,
Munci Yagci,
Alessandra Larocca ,
Abraham S. Kanate,
Filiz Vural,
Nicola Cascavilla,
Supratik Basu,
Peter Johnson,
Peter Byeff,
Marek Hus,
Paula Rodríguez-Otero,
Ercan Muelduer,
Pekka Anttila
and other authors.
,
Philippe Moreau,
Munci Yagci,
Alessandra Larocca ,
Abraham S. Kanate,
Filiz Vural,
Nicola Cascavilla,
Supratik Basu,
Peter Johnson,
Peter Byeff,
Marek Hus,
Paula Rodríguez-Otero,
Ercan Muelduer,
Pekka Anttila
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 